AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01340287 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: 2- plain low-fat dairy fermented product (drinkable) without plant sterols-esters
Description: 2 = Intervention 2 (1 control product/day)
Study NCT01617096 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Dapivirine Vaginal Ring
Description: Dosage form: vaginal ring Dosage: 25mg Frequency: monthly Duration: 12 months
Study NCT04341844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylene Blue
Description: 2mg/kg MB diluted with normal saline into total 50 ml volume intravenous administration after induction of anesthesia within one hour.
Study NCT04341844 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: normal saline in total 50 ml volume intravenous administration after induction of anesthesia within one hour.
Study NCT04497246 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: Data collection by means of various questionnaires
Study NCT00624130 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yasmin 20
Description: Yasmin 20, 24-d regimen vs Mercilon, Tablet p.o. (oral)
Study NCT00624130 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mercilon
Description: Mercilon, 24-d regimen vs Yasmin 20 , Tablet p.o. (oral)
Study NCT01745627 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 755nm Alex laser
Study NCT01847638 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prolensa (bromfenac 0.07%)
Description: Comparison of Prolensa (bromfenac ophthalmic solution) 0.07% QD vs. Ilevro (nepafenac ophthalmic suspension) 0.3% QD for Treatment of Ocular Inflammation Associated with Cataract Surgery
Study NCT01847638 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ilevro (nepafenac 0.3%)
Description: Comparison of Prolensa (bromfenac ophthalmic solution) 0.07% QD vs. Ilevro (nepafenac ophthalmic suspension) 0.3% QD for Treatment of Ocular Inflammation Associated with Cataract Surgery
Study NCT04185324 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard zippering vest
Description: Standard zippering vest used to teach zippering
Study NCT04185324 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modified zippering vest
Description: Modified zippering vest used to teach zippering, along with related story
Study NCT02154269 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment with G-CSF (Granulocyte colony stimulating factor)
Description: Subjects will be randomly assigned to receive treatment with G-CSF (10mg/kg/day) for five days, during 4 cicles.
Study NCT02154269 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo saline
Description: Subjects will be randomly assigned to receive treatment saline for five days, during 4 cicles.
Study NCT01937208 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: intensity modulated radiation therapy in both arms
Study NCT01937208 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: intensity modulated radiation therapy in both arms
Study NCT01937208 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: concurrent chemotherapy with radiation
Description: docetaxel plus cisplatin were used weekly in both arms
Study NCT01937208 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: concurrent chemotherapy with radiation
Description: docetaxel plus cisplatin were used weekly in both arms
Study NCT02190435 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stryker ADAPT computer-assisted navigation
Description: Adaptive Positioning Technology for Gamma 3
Study NCT02190435 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional technique
Description: Conventional Technique
Study NCT02083445 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: cognitive activities
Description: Participants followed a day of cognitive activities 1 day (1 hour/day) per week during 12 weeks.
Study NCT02083445 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise program
Description: Exercise program of endurance, resistance and proprioception exercises, comprising three sessions per week and muscle electro-stimulation was applied using the Compex Vitality® vascular and capillarization program with electrodes fixed in quadriceps and abdominal muscles or cycling exercise.
Study NCT02083445 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Muscle electro-stimulation
Description: A program of intermittent hypobaric hypoxia and muscle electro-stimulation of 3 days (3 hours/day) per week during 12 weeks
Study NCT02083445 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent hypobaric hypoxia
Study NCT03408080 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BHV-4157
Description: BHV-4157 is a glutamate modulating drug that is being developed for eventual commercial use in the treatment of spinocerebellar ataxia (SCA). This is currently no approved medication indicated for SCA.
Study NCT01429012 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal Stem Cells
Description: Mesenchymal Stem Cells. Dose= 40 X 10E6 in 2 ml. Frequency = one injection. If no evidence of a callus after 6 months a second injection can be proposed.
Study NCT01429012 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Culture medium without MSC.
Description: 2 ml of culture medium.
Study NCT03943511 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oral Antibiotics-Close Monitoring
Description: To receive oral antibiotics and close monitoring, defined as twice weekly telephone calls by a member of the care team, of their chest tube and valve.
Study NCT03943511 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: No calls from the care team but waiting for the subject to contact the care team when the air leak has stopped.
Study NCT02928393 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Basmisanil
Description: Basmisanil immediate-release granules at a dose of 240 mg will be given orally twice daily for 90 days.
Study NCT02928393 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matched to basmisanil immediate-release granules will be given orally twice daily for 90 days.
Study NCT00631722 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quatiapine Fumarate
Description: 600-750mg/day
Study NCT00631722 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Haloperidol
Description: 12-20mg/day
Study NCT00575822 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NDO Full-thickness Plicator
Description: A low-profile (≤6mm) gastroscope was advanced and an EGD followed by Savary wire placement was performed. The gastroscope was then removed and the Plicator was advanced directly over the wire and into the stomach. The gastroscope was re-introduced through the Plicator, and the Plicator was retroflexed under direct endoscopic visualization to the anterior gastric cardia, approximately 1cm below the gastroesophageal (GE) junction. The Plicator arms were opened and the endoscopic tissue retractor was advanced deeply into the gastric cardia. The gastric wall was then retracted into the open arms of the Plicator. The arms were closed and a single, transmural pledgeted suture was deployed. The Plicator and gastroscope were then removed and the gastroscope re-inserted to evaluate the post-plication GE junction.
Study NCT00575822 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Control
Description: The sham procedure was identical to the treatment procedure through the positioning of the retroflexed Plicator 1cm below the GE junction. The Plicator instrument remained in this position for 15 minutes, based on average procedure times established in previous studies. During the sham procedure, physician investigators were required to talk through the procedure steps to maintain the patient blind.
Study NCT02615717 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attention Bias Modification
Description: comparison of treatment versus control
Study NCT02615717 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention Bias Modification
Description: comparison of treatment versus control
Study NCT03619148 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High-Flow Humidified Nasal Oxygen
Description: High-Flow Humidified Nasal Oxygen
Study NCT03619148 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: High-Flow Humidified Nasal Oxygen
Description: High-Flow Humidified Nasal Oxygen
Study NCT01617096 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Ring
Description: Vaginal ring containing no drug substance
Study NCT02472639 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ostom-i Alert Sensor
Description: Wear the Ostom-i Alert Sensor
Study NCT02472639 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No Ostom-i Alert Sensor
Description: Patient will not use device
Study NCT01567527 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intramuscular (IM) Depot Aripiprazole
Description: Formulation: Intramuscular (IM) Depot Aripiprazole Formulation 400 mg or 300 mg, once a month injection
Study NCT01567527 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intramuscular (IM) Depot Placebo
Description: Formulation: Intramuscular (IM) Depot Placebo 400 mg or 300 mg, once a month injection
Study NCT01011413 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Efavirenz 600mg
Description: 3 x EFV 200 milligram (mg) tablets once daily
Study NCT01011413 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efavirenz 400mg
Description: 2 x EFV 200 milligram (mg) tablets plus 1x matched EFV placebo tablet once daily
Study NCT03655977 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-NODAGA-E[c(RGDyK)]2
Description: 200 MBq 68Ga-NODAGA-E\[c(RGDyK)\]2 will be administered before external beam radiation therapy (EBRT).
Study NCT03655977 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET/MRI scan instead of only MRI
Description: Following injection of RGD-PET the patients will be subjected to PET/MRI of the pelvic for planning external beam radiation therapy.
Study NCT03655977 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-NODAGA-E[c(RGDyK)]2
Description: 200 MBq 68Ga-NODAGA-E\[c(RGDyK)\]2 will be administered before brachytherapy (BT).
Study NCT03655977 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET/MRI scan instead of only MRI
Description: Following injection of RGD-PET the patients will be subjected to PET/MRI of the pelvic for planning brachytherapy.
Study NCT03255980 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Xonrid® gel
Description: Water based gel for the management of toxicity skin symptoms induced by Radiotherapy
Study NCT03255980 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Xonrid® gel
Description: Water based gel for the management of toxicity skin symptoms induced by Radiotherapy
Study NCT03255980 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Standard of care suggested by MASCC' Skyn Toxicity Study Group guidelines
Study NCT01847950 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Short-chain fructo-oligosaccharides
Description: Short-chain fructo-oligosaccharides are consummed at 5g/day for 6 weeks
Study NCT01847950 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Study NCT04345822 — intervention group
Intervention type: PROCEDURE
Intervention: Decompression surgery
Description: The surgeries aim to relieve the myelopathy from cord compression
Study NCT02123823 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus
Description: 10mg dose
Study NCT02123823 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: at recommended dose as per Phase I data
Study NCT02123823 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Dose escalation (24-48 patients) in Phase I. 3 dose levels depending on the dose cohort explored: 5mg, 7,5mg and 10mg
Study NCT02123823 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: Fixed dose at 25mg
Study NCT02123823 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 836845
Description: Human monoclonal antibody at recommended dose as per Phase I data
Study NCT02123823 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 836845
Description: Human monoclonal antibody. Dose escalation (24-48 patients) in Phase I. 2 dose levels (high or low) depending on the dose cohort explored
Study NCT02123823 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exemestane
Description: Fixed dose at 25mg
Study NCT02532192 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belinostat
Description: Dose Escalation Phase Starting Dose: 200 mg/m2/d by vein on Days 1 and 2 of a 21 day cycle.~Dose Expansion Starting Dose: Maximum tolerated dose from Dose Escalation Phase.
Study NCT02532192 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Dose Escalation and Dose Expansion Phases: 375 mg/m2 by vein on Day 2 of a 21 day cycle.
Study NCT02532192 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Dose Escalation and Dose Expansion Phases: 100 mg/m2 by vein on Day 2 of a 21 day cycle
Study NCT02532192 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Dose Escalation Phase: 2 g/m2 by vein on Day 3 of a 21 day cycle. Two doses given every 12 hours.~Dose Expansion Phase: 2g/m2 by vein on Day 2 of a 21 day cycle. Two doses given every 12 hours.
Study NCT01892527 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tivantinib (ARQ197)
Description: Eligible subjects will be treated with tivantinib (ARQ 197) at a dose of 360 mg twice daily (a total daily dose of 720 mg) orally in a continuous manner and cetuximab (Erbitux) at a dose of 500 mg/mq i.v. every 2 weeks.
Study NCT01492647 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ 10229570-AAA 1.2%
Description: One single application of 2.5 mL of the cream will be applied to the face, neck, shoulders, chest and to the upper back areas.
Study NCT01492647 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ 10229570-AAA 3.6%
Description: One single application of 2.5 mL of the cream will be applied to the face, neck, shoulders, chest and to the upper back areas.
Study NCT02532192 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dose Escalation and Dose Expansion Phases: 40 mg by mouth on Days 2 - 5 of a 21 day cycle.
Study NCT02532192 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Description: 500 mg by mouth twice daily for 10 days.
Study NCT02532192 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluconazole
Description: 100 mg by mouth daily for 10 days.
Study NCT02488057 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liraglutide
Description: Active comparator. See arm descriptions.
Study NCT02488057 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Weight loss
Description: Active comparator. See arm descriptions.
Study NCT01492647 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Color-matched vehicle containing 0 mg of JNJ 10229570-AAA
Description: One single application of 2.5 mL of the color-matched vehicle will be applied to the face, neck, shoulders, chest and to the upper back areas.
Study NCT03206749 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-150
Description: Participants received VX-150 1500 milligram (mg) as first dose, followed by VX-150 750 mg dose every 12 hours (q12h) for 2 days.
Study NCT03953586 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Bubble suction test and tubal peristalsis
Description: Efficacy of this test in cases of hydrosalpnix (group A) and normal tubes (group B)
Study NCT03567291 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TEV-50717
Description: 6, 9, and 12 mg oral tablets
Study NCT03567291 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator
Study NCT04942353 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home-based Exercise Rehabilitation.
Description: Based on physical therapist or exercise physiologist assessment, subjects will receive an individualized exercise prescription for frequency, duration, and intensity of walking and strength training (including exercises using light-weight hand-weights and upper and lower body exercises using resistance bands). Research team will provide updated exercise prescription based on Garmin watch/Datos app activity data and Datos app data (including Borg scale).
Study NCT04942353 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Patients receive a standardized recommendation to increase their walking activity to 30 minutes 5 days/week.
Study NCT03083730 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Narrow band UVB treatment (NB-UVB)
Description: NB-UVB light treatment NB-UVB light treatment for 3x/week for 12 weeks (36 visits)
Study NCT00226044 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omeprazole rectally 1mg/kg
Description: A single dose of 1 mg/kg rectally administered omeprazole.
Study NCT03206749 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HB/APAP
Description: Participants received HB 5 mg/APAP 325 mg every 6 hours (q6h) for 2 days.
Study NCT03206749 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants received placebo matched to VX-150 and HB/APAP for 2 days.
Study NCT01363817 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-906024
Study NCT03739944 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparotomic radical hysterectomy
Description: Laparotomic radical hysterectomy for patients without fertility requirement
Study NCT03739944 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparotomic radical trachelectomy
Description: Laparotomic radical hysterectomy for patients with fertility requirement
Study NCT03739944 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic radical hysterectomy
Description: Laparoscopic radical hysterectomy for patients without fertility requirement
Study NCT03739944 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic radical trachelectomy
Description: Laparoscopic radical hysterectomy for patients with fertility requirement
Study NCT01790438 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2605541
Study NCT01790438 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Human Insulin NPH
Study NCT01790438 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Antihyperglycemic Medications (OAM)
Study NCT01790438 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Antihyperglycemic Medications (OAM)
Study NCT03855917 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir 400mg [Sovaldi]
Description: Four weeks.
Study NCT03855917 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glecaprevir/pibrentasvir (300mg/120mg)
Description: Four weeks.
Study NCT00716404 — intervention group
Intervention type: DEVICE
Intervention: Targeted Renal Therapy
Description: Patient diagnosis, treatment, and follow-up are left to the discretion of the participating investigator. There are no requisites as to how patients should be managed as this is intended to be an observational study. No procedures other than usage of the Benephit Infusion System per its Instructions for Use are specifically required for participation in this study.
Study NCT03117049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-4538
Description: 360 mg solution intravenously for 30 min in every 3 weeks until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent.
Study NCT03117049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin at AUC 6 and Paclitaxel at 200 mg/m2 intravenously in every 3 weeks for up to 4 cycles and if deemed safe, Carboplatin and Paclitaxel may continue for up to a maximum of 6 cycles until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent.
Study NCT03117049 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin at AUC 6 and Paclitaxel at 200 mg/m2 intravenously in every 3 weeks for up to 4 cycles and if deemed safe, Carboplatin and Paclitaxel may continue for up to a maximum of 6 cycles until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent.
Study NCT05629104 — intervention group
Intervention type: OTHER
Intervention: There is no intervention since it is an observational study patients are treated according to clinical praxis
Description: No intervention
Study NCT01363817 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone